Immunotherapy for pancreatic ductal adenocarcinoma
Copyright policy )Immunotherapy for pancreatic ductal adenocarcinoma
AbstractPancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors. Here, we review the molecular components responsible for the immune‐privileged state in PDAC and provide an overview of the immunotherapeutic strategies for PDAC including vaccine therapy, checkpoint blockade, myeloid‐targeted therapy, and immune agonist therapy.
- University of Michigan–Ann Arbor United States
- University of Michigan–Flint United States
Pancreatic Neoplasms, Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Animals, Humans, Immunotherapy, Cancer Vaccines, Immune Checkpoint Inhibitors, Carcinoma, Pancreatic Ductal, Randomized Controlled Trials as Topic
Pancreatic Neoplasms, Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Animals, Humans, Immunotherapy, Cancer Vaccines, Immune Checkpoint Inhibitors, Carcinoma, Pancreatic Ductal, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).24 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!